Articles dans des revues avec comité de lecture (26)
  1. 1. Mileva, M., de Vries, E. E., Guiot, T., Wimana, Z., Deleu, A.-L., Schröder, C. P., Lefebvre, Y., Paesmans, M., Stroobants, S., Huizing, M. T., Aftimos, P., Tol, J., Van Der Graaf, W. T. A., Oyen, W. J. G., Vugts, D., Menke-van der Houven van Oordt, W. C., Brouwers, A. A., Piccart-Gebhart, M., Flamen, P., & Gebhart, G. (2024). Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ breast cancer, 10(1), 4. doi:10.1038/s41523-023-00610-6
  2. 2. Mokhtari, A., Casale, R., Salahuddin, Z., Paquier, Z., Guiot, T., Woodruff, H. H., Lambin, P., Van Laethem, J.-L., Hendlisz, A., & Bali, M. A. (2024). Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Diagnostics, 14(7), 712. doi:10.3390/diagnostics14070712
  3. 3. Llombart-Cussac, A., Prat, A., Pérez-García, J. M., Mateos, J., Pascual, T., Escrivá-de-Romani, S., Stradella, A., Ruiz Borrego, M., de las Heras, B., Keyaerts, M., Galvan, P., Brasó-Maristany, F., García-Mosquera, J. J., Guiot, T., Gion, M., Sampayo-Cordero, M., Di Cosimo, S., Pérez-Escuredo, J., de Frutos, M. A., Cortes, J., & Gebhart, G. (2024). Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. European journal of nuclear medicine and molecular imaging. doi:10.1007/s00259-024-06683-0
  4. 4. Shagera, Q. A., Karfis, I., Sideris, S., Guiot, T., Woff, E., Chanzá, N. M., Roumeguere, T., Gil, T., Flamen, P., & Artigas, C. (2023). Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel. Clinical nuclear medicine, 48(9), 775-780. doi:10.1097/RLU.0000000000004763
  5. 5. Paquier, Z., Chao, S.-L., Bregni, G., Sanchez Corujo, A., Guiot, T., Dhont, J., Gulyban, A., Levillain, H., Sclafani, F., Reynaert, N., & Bali, M. A. (2022). Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation. Physica medica, 103, 138-146. doi:10.1016/j.ejmp.2022.10.009
  6. 6. Paquier, Z., Chao, S.-L., Acquisto, A., Fenton, C., Guiot, T., Dhont, J., Levillain, H., Gulyban, A., Bali, M. A., & Reynaert, N. (2022). Radiomics software comparison using digital phantom and patient data: IBSI-compliance does not guarantee concordance of feature values. Biomedical Physics & Engineering Express, 8(6), 065008. doi:10.1088/2057-1976/ac8e6f
  7. 7. Woff, E., Salvatore, L., Marmorino, F., Genovesi, D., Critchi, G., Guiot, T., Ameye, L., Sclafani, F., Hendlisz, A., & Flamen, P. (2022). Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer. The Journal of nuclear medicine, 63(4), 549-555. doi:10.2967/jnumed.120.245357
  8. 8. Gombos, A., Venet, D., Ameye, L., Vuylsteke, P., Neven, P., Richard, V., Duhoux, F. F., Laes, J.-F., Rothé, F., Sotiriou, C., Paesmans, M., Awada, A., Guiot, T., Flamen, P., Piccart-Gebhart, M., Ignatiadis, M., & Gebhart, G. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ breast cancer, 7(1), 125. doi:10.1038/s41523-021-00331-8
  9. 9. Levillain, H., Burghelea, M., Duran Derijckere, I., Guiot, T., Gulyban, A., Vanderlinden, B., Vouche, M., Flamen, P., & Reynaert, N. (2020). Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer. EJNMMI Physics, 7(1). doi:10.1186/s40658-020-00345-4
  10. 10. Camera, S., Akin Telli, T., Woff, E., Vandeputte, C., Kehagias, P., Guiot, T., Critchi, G., Wissam, Y., Bregni, G., Trevisi, E., Pretta, A., Senti, C., Leduc, S., Gkolfakis, P., Hoerner, F., Rothé, F., Sclafani, F., Flamen, P., Deleporte, A., & Hendlisz, A. (2020). Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial. Cancers, 12(10), 2752. doi:10.3390/cancers12102752
  11. 11. Anciaux, M., Van Gossum, A., Wenglinski, C., Ameye, L., Guiot, T., Flamen, P., Demetter, P., Deleporte, A., Sclafani, F., Donckier De Donceel, V., Hendlisz, A., & Vandeputte, C. (2020). Fat density is a novel prognostic marker in patients with esophageal cancer. Clinical Nutrition ESPEN, 39, 124-130. doi:10.1016/j.clnesp.2020.07.007
  12. 12. Woff, E., Kehagias, P., Vandeputte, C., Ameye, L., Guiot, T., Paesmans, M., Hendlisz, A., & Flamen, P. (2019). Combining 18F-FDG PET/CT-based metabolically active tumor volume and circulating cell-free DNA significantly improves outcome prediction in chemorefractory metastatic colorectal cancer. The Journal of nuclear medicine, 60(10), 1366-1372. doi:10.2967/jnumed.118.222919
    13. << Précédent 1 2 3 Suivant >>